Description: Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Home Page: www.cloverbiopharma.com
Park Place
Shanghai,
200040
China
Phone:
86 28 8533 6966
Officers
| Name | Title |
|---|---|
| Dr. Peng Liang Ph.D. | Founder, Chief Scientific Officer & Chairman |
| Mr. Joshua G. Liang | CEO & Exec. Director |
| Ms. Aileen Wang | Chief Financial Officer |
| Dr. Berry Michael Ph.D. | Chief Technical Operation Officer |
| Elaine Qiu | Director of Investor Relations |
| Mr. Brian Krex | Gen. Counsel & Joint Company Sec. |
| Albert Liao | Exec. Director of Corp. Communications |
| Ms. Lily Yang | Chief People Officer |
| Ms. Htay Htay Han MBBS | Chief Medical Officer of Vaccine |
| Ms. Abigail Bracha Ph.D. | Sr. VP of Corp. Strategy & Bus. Devel. |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 3.8895 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.2921 |
| Price-to-Sales TTM: | 1153.7519 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 851 |